Cardarine (GW501516)

Overview

Cardarine, also known as GW501516 or endurobol, is a synthetic peroxisome proliferator-activated receptor delta (PPARδ) agonist developed in the 1990s by Ligand Pharmaceuticals and GlaxoSmithKline for treating metabolic and cardiovascular diseases like dyslipidemia, obesity, and hypertriglyceridemia.¹⁷ It acts as a metabolic modulator, enhancing fatty acid oxidation in tissues such as skeletal muscle and adipose tissue, potentially improving lipid metabolism and energy use.¹² Initially researched for conditions including type 2 diabetes and cardiovascular issues, development was halted in 2007 after animal studies showed rapid cancer development in multiple organs.⁷ Despite lacking human safety data and being banned by the World Anti-Doping Agency (WADA) as a metabolic modulator, it is misused by athletes and bodybuilders for fat loss and endurance enhancement.³⁴⁶ PPARδ agonists like Cardarine regulate genes involved in fat burning and inflammation reduction, but human use remains unapproved and potentially dangerous.²

Forms and Variations

Cardarine is primarily available as an oral synthetic small molecule in research chemical form, not as a regulated pharmaceutical.¹⁵ Common formulations include capsules, liquid solutions, or powders for oral administration, often sold on black markets or as research compounds despite bans.⁶⁸ Polymorph screening has identified five novel polymorphs, which are different crystal structures potentially affecting stability and solubility, though this is mainly relevant for pharmaceutical development.⁵ No standardized supplement variations exist due to its investigational status. Users choose liquid forms for precise dosing in performance enhancement contexts (10-20 mg/day), but bioavailability differences among polymorphs or formulations are unstudied in humans.⁸ Avoid all forms due to safety concerns; purity varies widely in unregulated products.³

Dosage and Administration

No official recommended dosages exist as Cardarine is not approved for human use and lacks clinical testing.⁴ Anecdotal reports from bodybuilders suggest 10-20 mg per day orally, often split into doses for performance enhancement.⁸ It is typically taken daily, sometimes cycled (e.g., 8-12 weeks on, with breaks), but no evidence supports safe protocols.³ Best practices are unknown; take with food to potentially reduce gastrointestinal upset, though unconfirmed. Due to cancer risks in animals, any use is strongly discouraged. Consult a healthcare provider before considering, but it is banned in sports and possibly unsafe orally.¹⁴⁷

Scientific Research and Mechanism of Action

Cardarine activates PPARδ receptors, regulating fatty acid oxidation and metabolic adaptations, particularly in skeletal muscle, adipose tissue, liver, and heart.¹² Preclinical studies show it increases beta-oxidation, reduces adiposity, improves insulin sensitivity, and enhances endurance by boosting oxidative muscle fibers.²³ In animal models, it lowered lipids, improved glucose levels in gestational diabetes, reduced liver fat and inflammation, protected cardiomyocytes, and aided diabetic wound healing.²³ However, high-dose rodent studies (3 mg/kg for 104 weeks) caused rapid cancers in liver, bladder, stomach, skin, prostate, and ovaries, leading to abandonment.⁷ Human trials were limited to Phase II for dyslipidemia before halt; no long-term safety data exists.¹ Research state: promising metabolic effects in animals, but severe carcinogenic risks preclude human use.⁴

Benefits and Potential Uses

Preclinical research suggests Cardarine may promote fat loss, increase endurance, and improve lipid profiles by enhancing PPARδ-mediated fat oxidation and energy metabolism.¹²³ Animal studies indicate benefits for dyslipidemia, obesity, type 2 diabetes (improved β-cell function, insulin sensitivity), hypertriglyceridemia, cardiovascular protection (reduced fibrosis, inflammation), and liver fat reduction.² It may accelerate diabetic wound healing and enhance cardiac function in heart failure models.³ Athletes misuse it for performance despite WADA ban, reporting fat burning and stamina gains, but no robust human evidence supports these.⁴⁶ Potential for metabolic disorders exists theoretically, but cancer risks outweigh unproven benefits; not recommended for any condition.⁷

Side Effects and Risks

Cardarine is possibly unsafe orally, with no human testing; animal studies showed rapid cancer development in multiple organs at high doses.⁴⁷ Common side effects are unknown due to lack of human data, but potential risks include liver toxicity, cardiovascular changes, and hormonal disruptions from metabolic modulation.² Preclinical concerns involve increased cellular proliferation and angiogenesis in cancer cell lines, though not confirmed in normal cells.² Athletes should avoid due to WADA prohibition and detection in hair testing.⁶⁸ Pregnant or breastfeeding individuals must avoid; possibly unsafe.⁴ Those with cancer history, liver disease, or metabolic disorders face heightened risks.¹

Interactions and Precautions

No specific drug interactions are documented due to absent human pharmacokinetics, but as a PPARδ agonist, it may affect lipid-lowering drugs, antidiabetics, or CYP450-related medications (non-substrate for key CYPs).¹ P-glycoprotein inhibition possible.¹ Precautions for all populations: untested in humans, carcinogenic in animals.⁷ Avoid in pregnancy, breastfeeding, children, elderly, or those with cancer predisposition.⁴ Athletes risk bans; prohibited by WADA.⁶ No data on surgical interactions, but altered metabolism may affect anesthesia or recovery. Consult physician; self-use dangerous.³

Impact on Biomarkers

Cardarine may lower triglycerides, LDL cholesterol, and improve HDL via PPARδ activation in animal models.¹³ It reduces blood glucose and insulin resistance markers, enhances fatty acid oxidation indicators.² Liver enzymes might elevate from fat reduction or toxicity; cancer biomarkers unstudied in humans. No reliable human data; monitor lipids, glucose, liver function if used illicitly.⁴

Overdose and Toxicity

Overdose risks unknown in humans; animal cancer at 3 mg/kg chronic dosing suggests high toxicity potential.⁷ Symptoms may include organ damage, though unspecified. No established safe upper limits; any dose risky due to carcinogenicity.⁴ Anecdotal 10-20 mg/day untested long-term.⁸ Seek immediate medical help for suspected overdose.

Disclaimer

The information provided in this document is for educational purposes only and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.